The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Ibrutinib maintenance in MCL
Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, outlines the preliminary results of a multicenter phase II trial assessing the efficacy and safety of ibrutinib maintenance for mantle cell lymphoma (MCL) after frontline induction. Results show ibrutinib maintenance is feasible in MCL patients who respond to frontline chemoimmunotherapy with or without transplant consolidation. Dr Abramson mentions that a longer follow-up is needed to assess clinical relevance of ibrutinib maintenance and the importance of measurable residual disease (MRD) status. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
